MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
3.430
-0.230
-6.28%
Closed 16:00 12/07 EST
OPEN
3.590
PREV CLOSE
3.660
HIGH
3.598
LOW
3.263
VOLUME
4.07K
TURNOVER
9.53K
52 WEEK HIGH
7.16
52 WEEK LOW
2.378
MARKET CAP
38.65M
P/E (TTM)
-1.0379
1D
5D
1M
3M
1Y
5Y
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress pos...
GlobeNewswire · 6d ago
Selecta Biosciences Names Blaine Davis CFO
Selecta Biosciences Names Blaine Davis CFO
MT Newswires · 11/28 08:47
Protara Therapeutics: Q3 Earnings Insights
Benzinga · 11/03 14:10
ArTara Therapeutics GAAP EPS of -$0.68 beats by $0.08
Seekingalpha · 11/03 13:18
Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview
- Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration, Phase 2 Study of TARA-002 in Lymphatic Malformations Expecte...
GlobeNewswire · 11/03 12:00
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 10/24 12:35
--HC Wainwright Cuts Protara Therapeutics' Price Target to $23 From $30, Maintains Buy Rating
--HC Wainwright Cuts Protara Therapeutics' Price Target to $23 From $30, Maintains Buy Rating
MT Newswires · 08/10 11:29
BRIEF-Protara Therapeutics Posts Q2 Loss Per Share $0.80
BRIEF-Protara Therapeutics Posts Q2 Loss Per Share $0.80
Reuters · 08/09 13:51
More
About TARA
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002 and IV Choline Chloride. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy, which is in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD).

Webull offers kinds of Protara Therapeutics Inc stock information, including NASDAQ:TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.